Maxim Group analyst Caroline Palomeque maintained a Buy rating on Genprex Inc (NASDAQ: GNPX) today and set a price target of $5. The company’s shares opened today at $2.35, close to its 52-week low of $2.16.
Palomeque wrote:
“Genprex announced that it has entered into a supply agreement with contract manufacturing organization (CMO) Aldevron.”
According to TipRanks.com, Palomeque is a 1-star analyst with an average return of -1.4% and a 42.9% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.
Genprex Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.45 and a one-year low of $2.16. Currently, Genprex Inc has an average volume of 73.82K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
